Phase II study of TAS-102 in patients with metastatic colorectal cancer
收藏NIAID Data Ecosystem2026-03-06 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2610203
下载链接
链接失效反馈官方服务：
资源简介：
Intervention name : TAS-102
Dosage And administration of the intervention : TAS-102 70 mg/m2 was administered orally twice a day for 5 days followed by 2 day rest and repeated two times this procedure.
Control intervention name : Placebo
Dosage And administration of the control intervention : Placebo was administered orally twice a day for 5 days followed by 2 day rest and repeated two times this procedure.
Primary outcome(s): Overall survival
To evaluate the overall survivals of TAS-102 versus placebo in patients with chemotherapy-refractory metastatic colorectal cancer
Study Design: Randomized, double-blind, placebo-controlled, parallel-group comparative study
创建时间：
2009-08-15
